Cadence Bank’s AstraZeneca AZN Stock Holding History

Cadence Bank’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,102	Closed	-$215K	–	242
2017 Q4	$215K	Buy	+3,102	New	+$209K	0.02%	236

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cadence Bank's AZN Position: Q1 2018 in Review

Cadence Bank sold out of AstraZeneca (AZN) in Q1 2018, closing a stake of 3,102 shares — an estimated $215K sold.

Cadence Bank first reported a position in AZN in Q4 2017 and held it in 1 quarter. The position peaked at $215K in Q4 2017. 519 funds tracked by Wall St. Rank hold AZN as of Q1 2018.

Cadence Bank reported no remaining AstraZeneca position as of Q1 2018 after selling out during the quarter.
Cadence Bank sold 3,102 AstraZeneca shares in Q1 2018, an estimated $215K.
Cadence Bank first reported a position in AstraZeneca in Q4 2017 and held it in 1 quarter.
Cadence Bank's AstraZeneca position peaked at $215K in Q4 2017.
519 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2018.

Based on Cadence Bank's 13F filing for Q1 2018, filed 3 May 2018.